Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Kimura

Showing results (31-40 of 365) with videos related to

Pageof 37
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2019
Mogamulizumab for the Treatment of Adult T-cell Leukemia/LymphomaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Cancer Science|January 21, 2025
Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of DecitabineTatsuro Watanabe, Keisuke Kidoguchi, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid LeukemiaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Leukemia Research|November 26, 2019
Role of cancer immunology in chronic myelogenous leukemiaHiroshi Ureshino, Takero Shindo, Shinya Kimura
Advanced Healthcare Materials|July 25, 2017
Newly Designed Silica-Containing Redox Nanoparticles for Oral Delivery of Novel TOP2 Catalytic Inhibitor for Treating Colon CancerLong Binh Vong, Shinya Kimura, Yukio Nagasaki
Chemistry, an Asian Journal|May 18, 2021
Enzymatic Hydrolysis-Responsive Supramolecular Hydrogels Composed of Maltose-Coupled Amphiphilic UreasRyohei Yoshisaki, Shinya Kimura, Masashi Yokoya, et al.
BMC Infectious Diseases|July 7, 2019
Influenza vaccination effectiveness for people aged under 65 years in Japan, 2013/2014 season: application of a doubly robust method to a large-scale, real-world datasetNatsumi Shibata, Shinya Kimura, Takahiro Hoshino, et al.
Ejhaem|December 18, 2024
IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CPHiroshi Ureshino, Kazuharu Kamachi, Keisuke Kidoguchi, et al.
Biological & Pharmaceutical Bulletin|March 12, 2015
Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511Masako Yokoo, Yasushi Kubota, Yoko Tabe, et al.
BMC Infectious Diseases|August 14, 2019
Correction to: Influenza vaccination effectiveness for people aged under 65 years in Japan, 2013/ 2014 season: application of a doubly robust method to a large-scale, real-world datasetNatsumi Shibata, Shinya Kimura, Takahiro Hoshino, et al.
Pageof 37

Showing results (31-40 of 365) with videos related to

Sort By:
Pageof 37
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2019
Mogamulizumab for the Treatment of Adult T-cell Leukemia/LymphomaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Cancer Science|January 21, 2025
Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of DecitabineTatsuro Watanabe, Keisuke Kidoguchi, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid LeukemiaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Leukemia Research|November 26, 2019
Role of cancer immunology in chronic myelogenous leukemiaHiroshi Ureshino, Takero Shindo, Shinya Kimura
Advanced Healthcare Materials|July 25, 2017
Newly Designed Silica-Containing Redox Nanoparticles for Oral Delivery of Novel TOP2 Catalytic Inhibitor for Treating Colon CancerLong Binh Vong, Shinya Kimura, Yukio Nagasaki
Chemistry, an Asian Journal|May 18, 2021
Enzymatic Hydrolysis-Responsive Supramolecular Hydrogels Composed of Maltose-Coupled Amphiphilic UreasRyohei Yoshisaki, Shinya Kimura, Masashi Yokoya, et al.
BMC Infectious Diseases|July 7, 2019
Influenza vaccination effectiveness for people aged under 65 years in Japan, 2013/2014 season: application of a doubly robust method to a large-scale, real-world datasetNatsumi Shibata, Shinya Kimura, Takahiro Hoshino, et al.
Ejhaem|December 18, 2024
IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CPHiroshi Ureshino, Kazuharu Kamachi, Keisuke Kidoguchi, et al.
Biological & Pharmaceutical Bulletin|March 12, 2015
Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511Masako Yokoo, Yasushi Kubota, Yoko Tabe, et al.
BMC Infectious Diseases|August 14, 2019
Correction to: Influenza vaccination effectiveness for people aged under 65 years in Japan, 2013/ 2014 season: application of a doubly robust method to a large-scale, real-world datasetNatsumi Shibata, Shinya Kimura, Takahiro Hoshino, et al.
Pageof 37